BPC-157 TB-500 FAQ, answered from the record

Definition and Purpose

These answers cover what the BPC-157 TB-500 blend is and what the research has actually used it for. Each is a direct answer first, context second.

What is the BPC-157 and TB-500 blend used for in research?

In preclinical, mostly rodent research, BPC-157 has been studied for tendon, ligament, muscle, and wound repair, and TB-500 / Thymosin Beta-4 for cell migration, re-epithelialization, and angiogenesis ^[1][5]. The blend is a research-community pairing; no controlled study has tested the two together.

What is the Wolverine peptide blend?

Wolverine is a research-community name for a two-peptide pairing of BPC-157 (a synthetic 15-amino-acid gastric-juice-derived pentadecapeptide) and TB-500 (the synthetic Ac-LKKTETQ fragment of Thymosin Beta-4) ^[1][3]. It is not a single chemical entity or an approved product.

What is BPC-157 and TB-500?

BPC-157 is a cytoprotective, pro-angiogenic pentadecapeptide derived from a human gastric-juice protein ^[1]. TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) from the actin-binding region of Thymosin Beta-4 ^[3][8]. The Wolverine blend co-formulates the two.

What is the difference between BPC-157 and TB-500?

BPC-157 is a 15-amino-acid pentadecapeptide from a gastric-juice protein that acts via VEGFR2-Akt-eNOS angiogenesis and cytoprotection ^[1][2]. TB-500 is a 7-amino-acid Ac-LKKTETQ fragment of Thymosin Beta-4 that sequesters G-actin to regulate cell migration ^[3]. Different sizes, sources, and mechanisms.

Mechanism and Combination

These answers cover how each peptide works and what the "synergy" of the combination does — and does not — rest on.

Why are BPC-157 and TB-500 combined (the Wolverine stack)?

The rationale pairs BPC-157's local cytoprotective and angiogenic signal (VEGFR2-Akt-eNOS) with TB-500's cytoskeletal cell-migration signal (G-actin sequestration) ^[2][3]. The two are described as complementary but largely non-overlapping. The synergy is a theoretical extrapolation, not a controlled-study finding.

Is there any study showing BPC-157 and TB-500 work better together (synergy)?

No. No peer-reviewed study defines a synergy ratio, dose, or endpoint for the combination. The 2025 HSS Journal systematic review of BPC-157 — 36 studies, only one human, "no clinical safety data" — makes no mention of TB-500 or combination use ^[9].

Are there human clinical trials on the BPC-157 + TB-500 combination?

There are none. Human data exist only for the individual constituents and are thin: three small BPC-157 pilot studies, and the human "TB-500" data are actually for full-length Thymosin Beta-4 (Phase 1 intravenous studies) ^[4][8]. The combination's human efficacy and safety are unproven.

How does TB-500 work (actin / Thymosin Beta-4)?

TB-500's LKKTETQ motif binds monomeric G-actin 1:1, sequestering it by capping both ends to prevent polymerization ^[3]. This regulates the actin dynamics that drive cell migration, re-epithelialization, and progenitor mobilization — a mechanism characterized largely for full-length Thymosin Beta-4 ^[4].

How does BPC-157 work compared to TB-500?

BPC-157 supplies a local cytoprotective and pro-angiogenic signal — VEGFR2-Akt-eNOS activation, nitric-oxide modulation, and growth-hormone-receptor sensitization of fibroblasts ^[1][2]. TB-500 supplies an intracellular actin-sequestration signal driving cytoskeletal migration ^[3]. They act through complementary but largely separate pathways.

Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)?

Both promote angiogenesis by distinct routes in animal and in-vitro models: BPC-157 up-regulates VEGFR2 with downstream Akt-eNOS signaling and improves blood-flow recovery in ischemic rat muscle ^[2]; Thymosin Beta-4 promotes endothelial migration and restored angiogenesis in aged rodents with otherwise poor wound healing ^[7].

Efficacy by Tissue

These answers cover the tissue-specific findings — wound, tendon and ligament, muscle — and the consistent caveat that the evidence is single-compound and largely rodent.

Does the BPC-157 TB-500 blend help wound healing?

In rat full-thickness wound models, Thymosin Beta-4 increased re-epithelialization by ~42% at 4 days and up to 61% at 7 days versus saline and raised collagen and angiogenesis; BPC-157 accelerated diverse wound types in rodents ^[5][1]. All evidence is animal-model and single-compound.

Does the BPC-157 TB-500 blend help tendon and ligament injuries?

In rats, BPC-157 accelerated healing of transected Achilles tendon and improved medial collateral ligament and tendon-to-bone healing; TB-500 / Thymosin Beta-4 enhanced rat MCL healing and acted as a myoblast chemoattractant ^[1][4]. All findings are animal-model and single-compound.

Does BPC-157 and TB-500 help muscle tears and recovery?

BPC-157 accelerated recovery of crushed rat gastrocnemius muscle and, in a 2025 study, muscle-to-bone reattachment after quadriceps detachment; injury-induced Thymosin Beta-4 recruits myoblasts ^[1][4]. No human or combination muscle-recovery trial exists.

Dose, Route, and Handling

These answers cover the practical dosing and reconstitution questions, with the same honest frame throughout: no validated dose for the blend.

How much BPC-157 and TB-500 should be used per week?

There is no validated weekly dose for the blend. Animal studies express BPC-157 per body weight (often ~10 microg/kg or ~10 ng/kg) and used TB-500 / Thymosin Beta-4 across a wide range — for example 150 microg twice weekly intraperitoneally in one six-month mouse study ^[1][4]. None translates to a human weekly blend dose.

What is the half-life of BPC-157 and TB-500?

No validated human pharmacokinetic half-life exists for either constituent at research doses, and none for the blend. BPC-157 elimination half-life was under 30 minutes in a rat/dog study; human intravenous Thymosin Beta-4 showed dose-proportional pharmacokinetics with half-life rising at higher doses, but no specific half-life is established for the TB-500 heptapeptide ^[4].

How do you reconstitute a BPC-157 / TB-500 blend (10mg)?

Both constituents are supplied as lyophilized powders reconstituted in bacteriostatic or sterile water and refrigerated; a common community practice is to reconstitute the two separately or in a shared vial ^[1]. Product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed.

How often should you inject BPC-157 and TB-500?

No validated blend frequency exists. The underlying rodent studies used predominantly intraperitoneal dosing on study-specific schedules — for example one six-month mouse Thymosin Beta-4 study used 150 microg twice weekly ^[4]. Community "loading then maintenance" blend protocols have no controlled-trial basis.

How do you cycle BPC-157 and TB-500?

No validated cycle exists. Community "loading then maintenance" schedules and fixed-ratio vials (e.g. 10 mg + 10 mg) have no basis in controlled human trials. Mixed and non-monotonic preclinical results — 18 mg/kg Thymosin Beta-4 gave no benefit in one rat study — undercut "more is better" loading rationales ^[4].

Safety and the Tumor Signal

These answers cover the safety and tumor signal questions honestly: no controlled human safety data for the blend, and a real theoretical concern around Thymosin Beta-4.

What are the side effects of BPC-157 and TB-500?

There are no controlled human safety data for the blend; the 2025 HSS Journal review found "no clinical safety data" for BPC-157 ^[9]. A key theoretical concern is that Thymosin Beta-4's pro-angiogenic and pro-migratory properties have been implicated in tumor metastasis and angiogenesis ^[4].

Does TB-500 cause cancer or promote tumor growth?

Thymosin Beta-4 has been implicated in tumor metastasis and angiogenesis: the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression ^[4]. This is a safety consideration, not a demonstrated effect of the blend in humans; long-term human data are absent.

Is TB-500 bad for your heart?

Full-length Thymosin Beta-4 has been studied in cardiac-repair models and intravenous human Phase 1 studies were well tolerated, but the TB-500 heptapeptide has no controlled human cardiac-safety data ^[4]. In a six-month dystrophic-mouse study, chronic Thymosin Beta-4 did not improve cardiac function. Long-term human safety is unknown.

Regulatory and Access

These answers summarize the regulatory record; the Wolverine legal status and 503A access page covers it in full and cites FDA.

Are BPC-157 and TB-500 FDA approved or banned by WADA?

Neither is FDA-approved for human use and the blend has no approved indication. In 2023 FDA placed both in 503A Category 2 — bulk substances identified as possibly presenting significant safety risks — so neither is within FDA's enforcement-discretion policy for compounding ^[12]. Both constituents are also prohibited by WADA (BPC-157 under S0; TB-500 / Thymosin Beta-4 under prohibited peptide and growth-factor categories).

Is Wolverine legal?

Neither constituent is an FDA-approved drug and the blend has no approved therapeutic indication; both are sold by research suppliers for laboratory use only ^[12]. Both are currently 503A Category 2 and are not within FDA's enforcement-discretion policy for compounding, and both are WADA-prohibited.

Can you get BPC-157 from a compounding pharmacy?

Currently, access is restricted. FDA placed BPC-157 in 503A Category 2 — bulk substances not within its enforcement-discretion policy — effective with the September 29, 2023 list update, so it is not eligible for routine 503A compounding while that status stands ^[12]. BPC-157 is on the July 23-24, 2026 PCAC agenda as a 503A bulks-list candidate — a scheduled evaluation, not a change in current status ^[13].

What is the FDA 503A status of Wolverine?

Both components are FDA 503A Category 2 bulk substances today, effective with the September 29, 2023 update, and neither is FDA-approved, so the blend has no current 503A compounding pathway ^[12]. Both are on the July 23-24, 2026 PCAC agenda as 503A bulks-list candidates — a scheduled review, not a decision ^[13].